Bayer fuels breakup talk by putting Roundup business into separate unit

• The new Ruveon division will handle all aspects of U.S. Roundup sales including pricing, production and logistics, while remaining part of Bayer's business structure
• Last week's Supreme Court ruling in Bayer's favor is expected to 'effectively cap the glyphosate exposure within existing provisions,' prompting Deutsche Bank to upgrade Bayer from 'hold' to 'buy'
• Bayer maintains that decades of studies show glyphosate is safe and does not cause cancer, despite ongoing litigation accusing the company of failing to warn users of health risks

Bayer Consolidates Roundup Business into Separate Unit Following Legal Victory

German pharmaceutical and crop science giant Bayer announced Thursday it is consolidating its U.S. Roundup weedkiller business into a new standalone unit called Ruveon. The move comes less than a week after the U.S. Supreme Court ruled in Bayer's favor, blocking thousands of state-court lawsuits related to the glyphosate-based product.

Key Details:

• Ruveon will remain under Bayer ownership and manage all U.S. Roundup operations, including pricing, production, and logistics
• The restructuring is part of Bayer's Crop Science division's five-year strategic plan focused on growth, resilience, and profitability
• Bayer acquired Roundup through its $63 billion purchase of Monsanto in 2018, which subsequently became a major liability due to cancer-related litigation
• Lawsuits have accused Bayer of failing to warn users that glyphosate causes cancer, though the company maintains decades of studies prove the ingredient is safe

Market Implications:

Following last week's Supreme Court ruling, Deutsche Bank upgraded Bayer from "hold" to "buy," stating the decision should "effectively cap the glyphosate exposure within existing provisions." The separate unit structure positions Ruveon as a "more nimble and well-positioned player" in the commodity-based market, suggesting potential for improved operational efficiency and competitiveness.

The consolidation fuels speculation about a possible future breakup or divestiture, as isolating the controversial business line could facilitate a sale or spin-off. Bayer is currently the only U.S. manufacturer of glyphosate, giving the new unit significant market positioning despite ongoing reputational challenges.